Following a limited submission
AWMSG advice |
|||
| Status: Recommended | |||
Bortezomib (Velcade®) 3.5 mg subcutaneous injection is recommended as an option for use within NHS Wales:
|
|||
|
|||
Medicine details |
|||
| Medicine name | bortezomib (Velcade®) | ||
| Formulation | 3.5 mg powder for solution for subcutaneous injection | ||
| Reference number | 1254 | ||
| Indication | In combination with melphalan and prednisone for the treatment of patients with previously untreated multiple myeloma who are not eligible for high-dose chemotherapy with haematopoietic stem cell transplantation; and as monotherapy for the treatment of progressive multiple myeloma in patients who have received at least 1 prior therapy and who have already undergone or are unsuitable for haematopoietic stem cell transplantation |
||
| Company | Janssen-Cilag Ltd | ||
| BNF chapter | Malignant disease & immunosuppression | ||
| Submission type | Limited | ||
| Status | Recommended | ||
| Advice number | 3812 | ||
| NMG meeting date | 07/11/2012 | ||
| AWMSG meeting date | 12/12/2012 | ||
| Ratification by Welsh Government | 16/01/2013 | ||
| Date of issue | 23/01/2013 | ||
| Date of last review | November 2022 | ||
| Further information This appraisal recommendation was reviewed in November 2022. No new evidence was identified that is likely to significantly affect the current recommendation. Therefore, this recommendation has been transferred to AWMSG’s static list of medicine recommendations |
|||